Assembly Biosciences Inc logo

ASMB - Assembly Biosciences Inc Share Price

$4.26 -0.1  -2.3%

Last Trade - 12/04/21

Small Cap
Market Cap £127.4m
Enterprise Value £-30.5m
Revenue £57.7m
Position in Universe 4669th / 6825
Unlock ASMB Revenue
Relative Strength (%)
1m -15.3%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -84.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 9.02 14.8 16.0 79.1 8.86 6.69
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, AssemblyBiosciences Inc revenues increased from $16M to $79.1M. Netloss decreased 36% to $62.2M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Basic Earnings per Shareexcluding Extraordinary Items increased from -$3.72 to-$1.75.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ASMB Revenue Unlock ASMB Revenue

Net Income

ASMB Net Income Unlock ASMB Revenue

Normalised EPS

ASMB Normalised EPS Unlock ASMB Revenue

PE Ratio Range

ASMB PE Ratio Range Unlock ASMB Revenue

Dividend Yield Range

ASMB Dividend Yield Range Unlock ASMB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ASMB EPS Forecasts Unlock ASMB Revenue
Profile Summary

Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated October 7, 2005
Public Since December 17, 2010
No. of Shareholders: 67
No. of Employees: 139
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 40,059,122
Free Float (0.0%)
Eligible for
ASMB Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ASMB
Upcoming Events for ASMB
Thursday 20th May, 2021
Assembly Biosciences Inc Annual Shareholders Meeting
Friday 11th June, 2021 Estimate
Assembly Biosciences Inc Annual Shareholders Meeting
Frequently Asked Questions for Assembly Biosciences Inc
What is the Assembly Biosciences Inc share price?

As of 12/04/21, shares in Assembly Biosciences Inc are trading at $4.26, giving the company a market capitalisation of £127.4m. This share price information is delayed by 15 minutes.

How has the Assembly Biosciences Inc share price performed this year?

Shares in Assembly Biosciences Inc are currently trading at $4.26 and the price has moved by -73.45% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Assembly Biosciences Inc price has moved by -82.1% over the past year.

What are the analyst and broker recommendations for Assembly Biosciences Inc?

Of the analysts with advisory recommendations for Assembly Biosciences Inc, there are there are currently 2 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Assembly Biosciences Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Assembly Biosciences Inc next release its financial results?

Assembly Biosciences Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Assembly Biosciences Inc dividend yield?

Assembly Biosciences Inc does not currently pay a dividend.

Does Assembly Biosciences Inc pay a dividend?

Assembly Biosciences Inc does not currently pay a dividend.

When does Assembly Biosciences Inc next pay dividends?

Assembly Biosciences Inc does not currently pay a dividend.

How do I buy Assembly Biosciences Inc shares?

To buy shares in Assembly Biosciences Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Assembly Biosciences Inc?

Shares in Assembly Biosciences Inc are currently trading at $4.26, giving the company a market capitalisation of £127.4m.

Where are Assembly Biosciences Inc shares listed? Where are Assembly Biosciences Inc shares listed?

Here are the trading details for Assembly Biosciences Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ASMB
What kind of share is Assembly Biosciences Inc?

Based on an overall assessment of its quality, value and momentum, Assembly Biosciences Inc is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Assembly Biosciences Inc share price forecast 2021?

Shares in Assembly Biosciences Inc are currently priced at $4.26. At that level they are trading at 0.161% discount to the analyst consensus target price of 0.00.

Analysts covering Assembly Biosciences Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.196 for the next financial year.

How can I tell whether the Assembly Biosciences Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Assembly Biosciences Inc. Over the past six months, the relative strength of its shares against the market has been -75.61%. At the current price of $4.26, shares in Assembly Biosciences Inc are trading at -64.39% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Assembly Biosciences Inc PE Ratio?

We were not able to find PE ratio data for Assembly Biosciences Inc.

Who are the key directors of Assembly Biosciences Inc?

Assembly Biosciences Inc's management team is headed by:

Myron Holubiak - IND
Anthony Altig - IND
Richard DiMarchi - IND
William Ringo - NEC
Jacqueline Papkoff - SVP
Steven Knox - SVP
David Houck - SVP
John McHutchison - PRE
Thomas Joseph Russo - CFO
Luisa Stamm - OTH
Jason Okazaki - OTH
William Delaney - CSO
Gina Consylman - IND
Nicole White - SVP
Who are the major shareholders of Assembly Biosciences Inc?

Here are the top five shareholders of Assembly Biosciences Inc based on the size of their shareholding:

Armistice Capital LLC Hedge Fund
Percentage owned: 6.55% (2.62m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.06% (2.43m shares)
Satter Management Co., L.P. Private Equity
Percentage owned: 5.56% (2.23m shares)
Consonance Capital Management LP Hedge Fund
Percentage owned: 4.92% (1.97m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.87% (1.95m shares)
Similar to ASMB
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.